New principles for the treatment of diffuse pulmonary emphysema
Related Experiment Video
Updated: Oct 30, 2026

A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis
Published on: January 16, 2026
1Department of Pulmonary Medicine, Karolinska Hospital, Stockholm, Sweden.
Abstract:
Emphysema is due to destruction of lung tissue but the main cause of the dyspnoea is a diminished elasticity of the lungs. Medical therapy, such as bronchodilation, corticosteroids, and treatment of intercurrent infections, can give temporary relief. Long-term oxygen treatment can improve and prolong life in patients with severe epmphysema. Lung transplantation is a final option in selected patients. Rehabilitation including exercise training will cause increase in maximal exercise tolerance and decrease of dyspnoea, and thereby an improvement of quality of life. In recent years surgical reduction of the lung volume has been reintroduced and in selected cases given dramatic results. The goal is to reduce the volume in both lungs with about 30%. Depending on the distribution of the emphysema, pieces of the upper or lower lobes will be removed. Sternotomy or bilateral thoracoscopy, using staplers, are the most common methods. Short-term results are good, with an improvement of FEV1 of 22-96%, improved arterial oxygen pressure, and a radical improvement of life quality. The impact on the daily life of the patient can be dramatic. The long-term results are still not well known, and many questions remain before volume reduction surgery can be regarded as an established form of treatment for emphysema, and randomized studies are badly needed.
Related Concept Videos
Chronic Obstructive Pulmonary Disease II: Emphysema
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
COPD: Management Using Bronchodilators and Corticosteroids
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Inhaled Medications
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
